《关于公司股票被实施其他风险警示相关事项的进展公告》 《2026年第一次临时股东会的法律意见书》 《关于2026年第一次临时股东会决议的公告》 近日，ST百灵发布《关于公司股票被实施其他风险警示相关事项的进展公告》。公告显示，公司于 2025年12月19日收到贵州证监局出具的《行政处罚事先告知书》，因公司披露的2019年、2020年、2021 年、2023年年报存在虚假记载，公司股票自2025年12月23日起被实施其他风险警示。公司已组织财务部 门及年审会计师事务所对相关年度财务会计报告进行核查，差错更正及追溯调整工作正在推进中。公司 董事会将持续完善内控体系，加强合规培训。截至公告披露日，公司生产经营正常，最终处罚结果以证 监会正式决定书为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年2月24日收盘，ST百灵（002424）报收于4.45元，较前一交易日上涨2.06%，最新总市值为 62.19亿元。该股当日开盘4.39元，最高4.57元，最低4.37元，成交额达1.17亿元，换手率为2.15%。 最新公告列表 ...

FF301 第 1 頁 共 10 頁 v 1.2.0 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00242 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | 3,017,661,785 | | | 0 | | 3,017,661,785 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | 3,017,661,785 | | | 0 | | 3,017,661,785 | 足夠公眾持股量的確認(註4) | 截至月份: | 2026年1月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 信德集團有 ...

Core Viewpoint - ST Bailing (002424) is expected to report significant losses for the year 2025, with net profit forecasts indicating a decline of up to 367.68% compared to the previous year [1][3]. Trading Information Summary - On January 30, ST Bailing's stock closed at 4.23 yuan, with a turnover rate of 1.18% and a trading volume of 143,100 hands, resulting in a transaction amount of 60.4362 million yuan [1]. - The net inflow of main funds was 5.93 million yuan, while retail funds saw a net inflow of 0.2137 million yuan, indicating mixed investor sentiment [1][3]. Performance Disclosure Highlights - ST Bailing forecasts a net profit loss for 2025 ranging from 60 million yuan to 90 million yuan, with a year-on-year decline of 278.46% to 367.68% [1][3]. - The company also anticipates a non-recurring net profit loss between 102 million yuan and 132 million yuan, reflecting a year-on-year decrease of 23.73% to 60.13% [1][3]. - The expected basic earnings per share for 2025 is projected to be between -0.04 yuan and -0.07 yuan [1]. Company Announcement Summary - The decline in ST Bailing's performance is attributed to multiple factors, including a slowdown in market demand, adjustments in medical insurance payment policies, intensified market competition, and rising fixed costs [1][3].

Group 1 - The company ST Bailin (002424.SZ) expects a net profit attributable to shareholders of -90 million to -60 million yuan for 2025, representing a year-on-year decline of 367.68% to 278.46% [1] - The net profit after deducting non-recurring gains and losses is projected to be -132 million to -102 million yuan for 2025 [1] - The overall business operations of the company remain stable, but are impacted by factors such as a slowdown in product market demand, adjustments in medical insurance payment policies, and intensified market competition [1] Group 2 - The company's operating revenue is expected to decline by approximately 20% year-on-year for 2025 [1] - Increased fixed asset scale leads to higher depreciation and amortization expenses, contributing to rising fixed costs that affect current performance [1] - The overall industry is under profit pressure due to changes in supply and demand across the industrial chain and inventory pressures [1]

Core Viewpoint - ST Bailin (002424.SZ) has received a patent application acceptance notice from the National Intellectual Property Administration for a traditional Chinese medicine formulation aimed at treating diabetes and its complications, which will enhance the company's core intellectual property protection [1] Group 1: Patent Application Details - The accepted patent application is for a "traditional Chinese medicine formulation for treating diabetes or its complications," based on years of research from the company's Tang Ning Tong Luo project [1] - The confidentiality protection scope includes formula composition, production processes, and multiple treatment areas, with a confidentiality period aligned with the "secret" confidentiality period under the National Confidentiality Law of the People's Republic of China [1] Group 2: Implications for the Company - The acceptance of this confidential patent will provide comprehensive and tighter core intellectual property protection for the Tang Ning Tong Luo project [1] - If the patent is ultimately granted, it will help the company avoid core technology leakage and accelerate clinical promotion and market transformation, thereby enhancing the company's core competitiveness [1]

Core Viewpoint - The recent announcements from Kelun Pharmaceutical indicate significant changes in institutional holdings, with notable fund managers adjusting their positions, reflecting a mixed sentiment in the market towards the company's future prospects [1] Group 1: Institutional Holdings Changes - Guo Lan, a well-known fund manager from China Europe Fund, reduced holdings in Kelun Pharmaceutical by 1.867 million shares in Q4 2025, following a previous reduction of 2.5371 million shares in Q3 2025 [1] - The Guangfa Multi-Factor Mixed Fund, managed by Tang Xiaobin, also exited the top ten shareholders of Kelun Pharmaceutical by reducing over 10 million shares in Q4 2025 [1] - In contrast, Zhao Bei from ICBC Credit Suisse increased holdings in Kelun Pharmaceutical by 2 million shares in Q4 2025, while the National Social Security Fund's 416 portfolio became a new top ten shareholder with 13.9445 million shares [1] Group 2: Market Sentiment and Future Outlook - Fund managers express optimism about the market, actively seeking investment opportunities, with a focus on sectors like automotive, semiconductors, and specialized equipment [1] - Liu Ankun from Rongtong Fund noted a "short-term active, long-term positive" market characteristic, supported by continuous inflow of incremental funds and strong sectoral performance in AI and non-ferrous metals [1] - The market is expected to continue its upward trend, driven by funding factors and potential catalysts in industries such as semiconductors and commercial aerospace, with a belief that the spring market rally may have already begun [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年12月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 信德集團有限公司 | | | 呈交日期: | 2026年1月6日 | | | I. 法定/註冊股本變動 | 不適用 | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00242 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 3,017,661,785 | | 0 | | 3,017,661,785 | | 增加 / 減少 (-) | | | ...

Core Viewpoint - Yichang Technology is undergoing a significant change in its controlling shareholder, transitioning to Chuzhou Weiran Technology Development Partnership, with the actual controller becoming the Chuzhou State-owned Assets Supervision and Administration Commission [1][7]. Group 1: Shareholder Change - The controlling shareholder of Yichang Technology will change from Gaojin Technology Industry Group to Weiran Partnership, which will hold 25.3347% of the shares after the transaction [9][10]. - The share transfer agreement indicates that Weiran Partnership will acquire the shares at a price of 8.16 yuan per share, totaling 850 million yuan [9][10]. Group 2: Financial Performance - As of December 22, Yichang Technology's stock price was 8.43 yuan per share, with a market capitalization of 3.467 billion yuan, reflecting a 5.64% increase [3]. - For the first three quarters of 2025, Yichang Technology reported a net profit attributable to shareholders of 38.08 million yuan, a decrease of 46.84% year-on-year, while the net profit after deducting non-recurring gains and losses was 27.30 million yuan, down 47.08% [15][16]. Group 3: Strategic Implications - The transaction is expected to optimize the company's equity structure and promote synergy with key industries in Chuzhou, enhancing business expansion, supply chain optimization, and technological upgrades [15]. - Weiran Partnership's managing partner is Chuzhou Urban Investment Xinchang Asset Management, which is indirectly controlled by Chuzhou Urban Investment Holding Group, a state-owned enterprise focused on infrastructure and industrial investment [15].

Group 1 - The core issue involves Guizhou Bailing's financial fraud, leading to administrative penalties from the Guizhou Securities Regulatory Bureau [1] - Guizhou Bailing's financial reports for 2019, 2020, 2021, and 2023 contained false records, resulting in a cumulative profit inflation of 65,472.60 million yuan and a profit reduction of 45,941.10 million yuan in 2023 [1] - The company will face a fine of 10 million yuan and warnings for its financial misconduct, while 10 responsible individuals, including Jiang Wei, will be fined a total of 15.6 million yuan and face a 10-year market ban [1] Group 2 - The Guizhou Securities Regulatory Bureau emphasizes a zero-tolerance policy towards financial fraud, aiming to enhance regulatory effectiveness and protect investor rights [2] - Guizhou Bailing is a pharmaceutical company involved in the research, production, and sales of traditional medicine, with key products including Yindan Xinnaotong soft capsules and Kesu Ting syrup [2]

Group 1 - Guizhou Baikang (002424) has been penalized by the Guizhou Securities Regulatory Bureau for financial fraud, with the company and related parties receiving an administrative penalty notice [2] - The company reported false financial data in its annual reports for 2019, 2020, 2021, and 2023, leading to a cumulative profit inflation of 65,472.60 million yuan and a profit reduction of 45,941.10 million yuan in 2023 [2] - The company's stock will be suspended for one day starting December 22 and will resume trading on December 23 under the risk warning label "ST Baikang" [2] Group 2 - The Guizhou Securities Regulatory Bureau emphasizes a zero-tolerance policy towards financial fraud, aiming to enhance regulatory effectiveness and deterrence [3] - The bureau focuses on key individuals such as actual controllers, major shareholders, directors, and senior executives, as well as intermediary institutions [3] - Guizhou Baikang is a pharmaceutical company involved in the research, production, and sales of苗药 (苗药) and has several key products contributing to its profits [3]